Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality
Open Access
- 9 July 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (7) , e2609
Abstract
Recently, the type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling and imaging studies of a murine model of type 2 diabetes, the C57BL/KLS-leprdb/leprdb (db/db) mouse. We compared cardiac gene expression profiles from three groups: untreated db/db mice, db/db mice after rosiglitazone treatment, and non-diabetic db/+ mice. Prior to sacrifice, we also performed cardiac magnetic resonance (CMR) and echocardiography. As expected, overall the db/db gene expression signature was markedly different from control, but to our surprise was not significantly reversed with rosiglitazone. In particular, we have uncovered a number of rosiglitazone modulated genes and pathways that may play a role in the pathophysiology of the increase in cardiac mortality as seen in several recent meta-analyses. Specifically, the cumulative upregulation of (1) a matrix metalloproteinase gene that has previously been implicated in plaque rupture, (2) potassium channel genes involved in membrane potential maintenance and action potential generation, and (3) sphingolipid and ceramide metabolism-related genes, together give cause for concern over rosiglitazone's safety. Lastly, in vivo imaging studies revealed minimal differences between rosiglitazone-treated and untreated db/db mouse hearts, indicating that rosiglitazone's effects on gene expression in the heart do not immediately turn into detectable gross functional changes. This study maps the genomic expression patterns in the hearts of the db/db murine model of diabetes and illustrates the impact of rosiglitazone on these patterns. The db/db gene expression signature was markedly different from control, and was not reversed with rosiglitazone. A smaller number of unique and interesting changes in gene expression were noted with rosiglitazone treatment. Further study of these genes and molecular pathways will provide important insights into the cardiac decompensation associated with both diabetes and rosiglitazone treatment.Keywords
This publication has 46 references indexed in Scilit:
- Hypoxia Inducible Factor-1 Upregulates Adiponectin in Diabetic Mouse Hearts And Attenuates Post-Ischemic InjuryJournal of Cardiovascular Pharmacology, 2008
- Selective modulation of promoter recruitment and transcriptional activity of PPARγBiochemical and Biophysical Research Communications, 2007
- Pioglitazone induces de novo ceramide synthesis in the rat heartProstaglandins & Other Lipid Mediators, 2007
- Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II–angiotensin type 1 receptor systemJournal of Molecular and Cellular Cardiology, 2006
- Adiponectin is synthesized and secreted by human and murine cardiomyocytesFEBS Letters, 2005
- Impact of PPARγ overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarraysAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Gene expression profiling of potential PPARγ target genes in mouse aortaPhysiological Genomics, 2004
- Treatment of type 2 diabeticdb/dbmice with a novel PPARγ agonist improves cardiac metabolism but not contractile functionAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Peroxisome Proliferator-Activated Receptor (PPAR) α and PPARβ/δ, but not PPARγ, Modulate the Expression of Genes Involved in Cardiac Lipid MetabolismCirculation Research, 2003
- PPARs of the HeartCirculation Research, 2003